Literature DB >> 20634901

Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.

Denise C Connolly1, Harvey H Hensley.   

Abstract

Epithelial ovarian cancer (EOC) is the most commonly fatal gynecologic malignancy in developed countries. Most EOC patients are diagnosed at advanced stage when disease has spread beyond the ovary. While many patients initially respond to surgery and chemotherapy, the long term prognosis is generally unfavorable, with recurrence and development of drug resistant disease. There is a critical need to identify new therapeutic agents that prolong disease-free intervals and effectively manage recurrent disease. Murine models of ovarian carcinoma are excellent models to study tumor biology in the search for new treatments for EOC. Described in this unit are methods for establishing xenograft or allograft models of EOC using ovarian carcinoma cell lines, in vivo imaging strategies for detection and quantification of EOC in transgenic and in xenograft/allograft models, and procedures for necropsy and pathological evaluation of experimental animals.

Entities:  

Year:  2009        PMID: 20634901      PMCID: PMC2904083     

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  62 in total

1.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Authors:  Daniela M Dinulescu; Tan A Ince; Bradley J Quade; Sarah A Shafer; Denise Crowley; Tyler Jacks
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

2.  The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression.

Authors:  D Coppola; B Saunders; L Fu; W Mao; S V Nicosia
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

3.  A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.

Authors:  Deyin Xing; Sandra Orsulic
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Maija-Riitta Ordén; Kirsi Ropponen; Veli-Matti Kosma; Seppo Heinonen; Seppo Yla-Herttuala
Journal:  Gynecol Oncol       Date:  2006-05-04       Impact factor: 5.482

5.  Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo.

Authors:  B R Davies; N Auersperg; S D Worsley; B A Ponder
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

6.  Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.

Authors:  Katherine V Clark-Knowles; Kenneth Garson; Jos Jonkers; Barbara C Vanderhyden
Journal:  Exp Cell Res       Date:  2006-10-03       Impact factor: 3.905

7.  Ovarian volume measurements in mice with high-resolution ultrasonography.

Authors:  Andrej Lyshchik; Stephen B Hobbs; Arthur C Fleischer; Dineo Khabele; Deok-Soo Son; John C Gore; Ronald R Price
Journal:  J Ultrasound Med       Date:  2007-10       Impact factor: 2.153

8.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

9.  Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens.

Authors:  X Fu; R M Hoffman
Journal:  Anticancer Res       Date:  1993 Mar-Apr       Impact factor: 2.480

10.  Ovarian tumors of the hen.

Authors:  T N Fredrickson
Journal:  Environ Health Perspect       Date:  1987-08       Impact factor: 9.031

View more
  18 in total

1.  Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.

Authors:  Benjamin G Bitler; Jasmine P Nicodemus; Hua Li; Qi Cai; Hong Wu; Xiang Hua; Tianyu Li; Michael J Birrer; Andrew K Godwin; Paul Cairns; Rugang Zhang
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

2.  Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Authors:  Kristy K Ward; Isabelle Tancioni; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Sean Uryu; Josephine Kim; David Tarin; Dwayne G Stupack; Steven C Plaxe; David D Schlaepfer
Journal:  Clin Exp Metastasis       Date:  2012-12-30       Impact factor: 5.150

3.  Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.

Authors:  Vijayalakshmi N Ayyagari; Nancy A Johnston; Laurent Brard
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

4.  A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer.

Authors:  Hsin-Yao Tang; Lynn A Beer; Tony Chang-Wong; Rachel Hammond; Phyllis Gimotty; George Coukos; David W Speicher
Journal:  J Proteome Res       Date:  2011-11-18       Impact factor: 4.466

5.  Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis.

Authors:  Priyanka Singh; Laura M Jenkins; Ben Horst; Victoria Alers; Shrikant Pradhan; Prabhjot Kaur; Tapasya Srivastava; Nadine Hempel; Balázs Győrffy; Eugenia V Broude; Nam Y Lee; Karthikeyan Mythreye
Journal:  Cancer Res       Date:  2018-03-13       Impact factor: 12.701

6.  In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer.

Authors:  Alexis B Cordero; Youngjoo Kwon; Xiang Hua; Andrew K Godwin
Journal:  J Vis Exp       Date:  2010-08-17       Impact factor: 1.355

7.  An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.

Authors:  Selene Nunez-Cruz; Denise C Connolly; Nathalie Scholler
Journal:  J Vis Exp       Date:  2010-11-28       Impact factor: 1.355

8.  Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Authors:  Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly
Journal:  Clin Cancer Res       Date:  2013-07-30       Impact factor: 12.531

9.  Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.

Authors:  Galina Gritsina; Fang Xiao; Shane W O'Brien; Rashid Gabbasov; Marisa A Maglaty; Ren-Huan Xu; Roshan J Thapa; Yan Zhou; Emmanuelle Nicolas; Samuel Litwin; Siddharth Balachandran; Luis J Sigal; Dennis Huszar; Denise C Connolly
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

10.  Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Authors:  T-V Do; F Xiao; L E Bickel; A J Klein-Szanto; H B Pathak; X Hua; C Howe; S W O'Brien; M Maglaty; J A Ecsedy; S Litwin; E A Golemis; R J Schilder; A K Godwin; D C Connolly
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.